[1] |
SONG Yan, GAO Linyan, ZHANG Yanping, LI Xiang, ZHANG Lan.
Application of medical failure mode and effect analysis in blood sample management in phase I clinical trials#br#
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(9): 1031-1036.
|
[2] |
ZHONG Zihang, CHEN Feng, YUAN Ying, CHENG Jiancheng, YU Xuanxuan, YANG Min, TAN Mingmin, ZHAO Yang, BAI Jianling, YU Hao.
A novel model-assisted design in phase I clinical trials: Bayesian optimal interval design
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(6): 640-648.
|
[3] |
YANG Haijing, YU Jicheng, WANG Jingjing, LI Nanyang, WU Jufang, ZHANG Hai, XUE Tao, DAI Weiguo, DING Tianling, CAO Guoying.
Risk management of biological agents in phase I clinical trials: Case sharing
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(1): 44-48.
|
[4] |
ZHU Songzhi.
Therapeutic effect and related factors of human fibrinogen on traumatic traumatic coagulopathy
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(6): 693-698.
|
[5] |
YANG Bo, SHI Dawei, ZHENG Zaoqian.
Pharmaceutical care on one case of hypobrinogenemia induced by hemocoagulase
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(8): 932-936.
|
[6] |
CAO Bei, GENG Yan, LI Juan.
Brief probe into the application of BEIS system of ECRFPlus in Phase I clinical trials
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(12): 1431-1437.
|
[7] |
YE Yujie, YUAN Weian, HE Min.
Implementation points of the urine sample collection in phase I clinical trial of drugs
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(12): 1438-1440.
|
[8] |
HUANG Ping, ZUO Rong, XIA Chun-hua, XIONG Yu-qing.
Brief introduction to phase I clinical trial subjects management
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(3): 320-322.
|
[9] |
FEI Xian-ming, CHEN Yan, WU Wan-fei, JIANG Lei, QIU Lian-nv, ZHOU Yong-lie.
Effects of Agrimoni Pilosa aqueous extract on platelet aggregation, coagulation function and hemorheology
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2013, 18(1): 10-16.
|
[10] |
ZHANG Zheng-fu, SHEN Yu-hong, LI Zheng-qi.
Problems in the recruitment and management of trial subjects for phase I clinical trials in China
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2012, 17(5): 481-484.
|
[11] |
FEI Xian-ming, ZHOU Yong-lie, QI Jin-wen, WU Jian-guo, QIU Lian-nv, WANG Zhen-ni.
In vitro inhibitory effects of papain on platelet aggregation
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2009, 14(8): 906-911.
|
[12] |
HAN Lian-he, CHEN Teng, FENG Guo-qing.
Protective effects of ligustrazine and sodium hyaluronate and contrast study on rabbit's postoperative pericardial adhesion
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2006, 11(6): 665-668.
|